Drug maker Cipla on Monday announced the launch of a generic version of anti-hepatitis drug Ledipasvir-Sofosbuvir in the domestic market.
The drug is used for treating the hepatitis C virus. About 12-18 million Indians are suffering from it while globally the number is about 185 million.
Last year, pharma company Gilead Sciences signed non-exclusive licencing agreements with seven companies, including Cipla, for the manufacture and distribution of the drug in India.
Cipla also announced the launch of a patient support programme to create awareness amongst people and to cater to existing patients.
Managing Director and Global Chief Executive Officer Subhanu Saxena said, “The launch of Ledipasvir-Sofosbuvir is a further step to facilitate the optimal treatment for patients suffering from genotype 1 hepatitis C virus.”
Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients, Cipla said.
The company’s current portfolio includes over 1,500 products across therapeutic categories.
Cipla was trading at Rs 646.15, up 0.62 per cent, on the BSE.